Skip to main content
SpringerLink
Log in

Travel-related costs of CAR T cell therapy high for diffuse large B cell lymphoma in the USA

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Snyder S, et al. Travel-Related Economic Burden of Chimeric Antigen Receptor T Cell Therapy Administration by Site of Care. Advances in Therapy : 18 Jul 2021. Available from: URL: http://doi.org/10.1007/s12325-021-01839-y

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Travel-related costs of CAR T cell therapy high for diffuse large B cell lymphoma in the USA. PharmacoEcon Outcomes News 884, 29 (2021). https://doi.org/10.1007/s40274-021-7936-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-021-7936-0

Search

Navigation